antibody against timp3 (R&D Systems)
Structured Review

Antibody Against Timp3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody against timp3/product/R&D Systems
Average 93 stars, based on 11 article reviews
Images
1) Product Images from "Transcriptomic and functional characterization of megakaryocytic-derived platelet-like particles: impaired aggregation and prominent anti-tumor effects."
Article Title: Transcriptomic and functional characterization of megakaryocytic-derived platelet-like particles: impaired aggregation and prominent anti-tumor effects.
Journal: Platelets
doi: 10.1080/09537104.2024.2449344
Figure Legend Snippet: Figure 7. Signaling axes promoting or inhibiting oncogenicity. (A) Schematic representation of potential signaling axes mediating platelet-PCa pro- oncogenic interactions and PLP-PCa anti-oncogenic interactions. (B) RNA-seq expression values in TPMs of components in the platelet-PCa cell signaling axes. (C) RNA-seq expression values of components in the PLP-PCa cell signaling axes. Data in (B) and (C) presented as the mean ± SEM of n = 44 for platelets and n = 8 independent determinations for PLPs (determinations for MEG-01- and K-562-derived PLPs combined). RNA-Seq TPM values for MDA and RC77 were from a single determination. Statistical analysis was performed using a t-test (*p < .05). (D) Far left panel depicts relative 48-hour matrigel invasion by MDA-PCa-2b (MDA) and RC77T/E (RC77) cells incubated with vehicle (veh) + 5 ug/ml IgG isotype control, PLP + IgG, or PLP + 5 ug/ml neutralizing antibody against TIMP3 (β-TIMP3). Middle panel depicts relative 24-hour caspase activity in MDA and RC77 cells incubated with vehicle (veh) + 5 ug/ml IgG isotype control, PLP + IgG, or PLP + 5 ug/ml neutralizing antibody α-vegfb. Far right panel depicts relative 24-hour caspase activity in MDA cells incubated with conditioned medium (CM) derived from 24-hour culturing of MEG-01 PLPs (CM1), PCa cells + PLPs (CM2), and PCa cells + PLPs + platelets (CM3). Closed and open bars indicate incubation with 5 ug/ml IgG or α-TIMP3, respectively. Cell:PLP ratio was 1:500 and Cell:PLP:platelet ratio was 1:500:500 for all experiments. Data presented as the mean ± SEM of n = 4 independent determinations and analyzed by ANOVA and Dunnett’s post-hoc test. *significantly different (p < .05) compared to corresponding control (veh-containing group). #Significantly different (p < .05) compared to corresponding IgG group. Abbreviations: RC77, RC77T/E; MDA, MDA-PCa -2b; ITGA2B, integrin alpha 2b; ITGB3, integrin beta 3; FN1, fibronectin 1; IL32, interleukin 32; EGF, epidermal growth factor; TGFA, transforming growth factor alpha; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; ERBB3, human epidermal growth factor receptor 3; EPHA, EPH receptor A; EFNA, ephrin A; TIMP3, tissue inhibitor of metalloproteinases 3; MMP15, matrix metalloproteinase 15; VEGFB, vascular endothelial growth factor B; FGFR1, fibroblast growth factor receptor 1; IGFBP4, insulin-like growth factor-binding protein 4; LPR6, low-density lipoprotein receptor-related protein 6.
Techniques Used: RNA Sequencing, Expressing, Derivative Assay, Incubation, Control, Activity Assay, Binding Assay
